Clinical trial · Interventional
LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia
LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia
NCT00526409CI-TRIAL-00015917LAL-AR-N-2005completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study objective is to improve the global results obtained with LAL-AR-93 study, reaching an event free survival between 60-70%. Identify patients with bad prognosis, with minimal residual disease,who can benefit of allogenic bone marrow transplantation
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Cytosine Arabinoside | Drug | Cytarabine | ALIAS |
| Daunorubicin | Drug | Daunorubicin | ALIAS |
| L-Asparaginase | Drug | Asparaginase | ALIAS |
| Methotrexate | Drug | Methotrexate | ALIAS |
| Prednisolone | Drug | Prednisolone | ALIAS |
| Vincristine | Drug | Vincristine | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To improve the global results obtained in PETHEMA LAL-AR-93 study in terms of events free time
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: * High risk children with acute lymphoblastic leukemia Exclusion Criteria: * Mature B-ALL (FABL3) * Mixed forms of ALL * Patients with coronary disorders, valvular or hypertensive cardiopathy * Patients with chronic liver disorders * Chronic pulmonary disorders * Renal insufficiency * Neurologic disfunctions * ECOG 3 and 4
References
Publications (0)
Data not yet available
No reference posted for this study.